Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by ...

Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...

A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly predicts Alzheimer's risk and progression.

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

A person’s “bioenergetic age”, or how youthfully their cells generate energy, might be a key indicator of whether they’re at ...